Trump Wants a Rate Cut to Boost Housing. It's Not That Simple
In President Donald Trump's view, there's one 'numbskull' to blame: Federal Reserve Chair Jerome Powell.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
US market avoids tariff impacts as outlook improves
Sales Summary According to preliminary estimates, US Light Vehicle (LV) sales grew by 7.3% YoY in July, to 1.39 million units. July 2025 had one additional selling day as compared to July 2024, meaning that sales were up by 4.1% YoY on a selling day-adjusted basis. The daily selling rate was measured at 53.6k units/day in July, up from 52.7k units/day in June. The annualized selling rate was estimated at 16.6 million units/year in July, up from 15.2 million units/year in June. Retail sales were estimated at 1.19 million units, up by 10.8% YoY, while fleet sales were thought to total 206k units, down by 4.5% YoY. OEM Analysis GM was once again the bestselling OEM in the market, with total sales of 237k units, and a market share of 17.0%. Despite a seemingly impressive monthly volume, GM's market share has now declined for three straight months. Toyota Group ranked second in July sales, on 218k units, for a 15.6% share, with the group's sales jumping by 19.9% YoY. Ford Group was in third place, on 182k units, but after a stellar Q2, the OEM's share fell back to a modest 13.1% in July. At a brand level, Toyota outsold Ford, by 187k units to 176k units. While it has been typical in recent times for Toyota to sell higher volumes than Ford, the reverse had been the case in June. Chevrolet was third, on 153k units. Model Analysis Despite a slightly quiet month for Ford overall, the F-150 was the nation's bestselling model once again in July, on 44.2k units – the F-150 has now held the top spot for four consecutive months. The Toyota RAV4 was in second on 39.8k units, while the Chevrolet Silverado came in third on 35.4k units. The ranking of the top three models was unchanged from June. The Chevrolet Equinox sold 31.8k units in July, its highest volume since March. Segment Analysis According to initial estimates, Compact Non-Premium SUV's market share was 21.5% in July, the segment's highest share since March. To some extent, however, this performance was upstaged by Midsize Non-Premium SUV, which achieved a market share of 17.2%, up by 2.0 pp on June's result, and the highest for the segment since May 2022. The segment was boosted by robust volumes from models such as the Toyota 4Runner and Hyundai Palisade. After two stronger months in May and June, the Large Pickup segment saw its market share ease back to 13.8% in July. David Oakley, Manager, Americas Sales Forecasts, GlobalData, said: 'There was little sign of tariffs negatively impacting the market in July. Automakers have made a point of absorbing the higher costs they are seeing, and some have even extended offers that were previously due to expire at the beginning of the July. Therefore, from the consumer's point-of-view, there was perhaps little to dissuade buyers from making purchases as normal. At the present time, OEMs are still vying for market share, rather than being overly concerned with protecting inventory. We should also bear in mind that for the majority of the month of July, the landscape regarding tariff rates in the longer-term was highly unclear. Automakers have therefore largely tried to maintain a business-as-usual approach, while mostly avoiding knee-jerk reactions in the face of uncertainty. The announcement that the tax credits available for Electric Vehicles (EVs) will be discontinued from September 30th appeared to notably boost sales of some EVs in July, an effect that we would expect to continue as we move through the next two months and the deadline looms larger'. Forecast Updates While OEMs have thus far largely adopted a 'holding pattern' approach to tariff uncertainty, this is not necessarily a strategy they can maintain indefinitely. Several automakers reported either outright financial losses in Q2, or large reductions in profitability due to the cost of absorbing tariffs. Recent trade deals with various countries have given greater clarity to the industry, as it appears that the benchmark rate will be 15% for countries outside of North America. Although the Trump administration raised tariffs on some Canadian goods to 35%, vehicles compliant with the USMCA trade agreement – which covers the vast majority of models sourced from Canada – will still be subject to 25% tariffs on the non-US content of the vehicle, and the same applies to Mexico. Nevertheless, the prospect remains of some vehicles sourced from the US's neighbors potentially incurring higher tariffs than a model imported from Japan, for example. In the longer-term, this seems unlikely to be sustained, but negotiations with Mexico, and particularly Canada, have been difficult. With an earlier-than-expected lowering of tariff rates, we now see US sales at around 15.7 million units in 2025, still down from almost 16.0 million units in 2024, but a considerably better outlook than would have been the case had the original tariffs remained in place without mitigation. This article was first published on GlobalData's dedicated research platform, the . "US market avoids tariff impacts as outlook improves – GlobalData" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
11 minutes ago
- Yahoo
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R&D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets NEW YORK, August 05, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we're confident in our ability to create further value for patients and our shareholders." David Denton, CFO and EVP of Pfizer: "Our robust second-quarter Revenue and EPS performance demonstrates our continued focus on commercial execution and operational efficiency. We raised our full-year 2025 Adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strategic priorities and deliver strong results for shareholders." OVERALL RESULTS Second-Quarter 2025 Revenues of $14.7 Billion, Representing 10% Year-over-Year Operational Growth Second-Quarter 2025 Reported(3) Diluted EPS of $0.51, and Adjusted(2) Diluted EPS of $0.78 Reaffirms Full-Year 2025 Revenue Guidance(1) in a Range of $61.0 to $64.0 Billion Raises Full-Year 2025 Adjusted(2) Diluted EPS Guidance(1) by $0.10 to a Range of $2.90 to $3.10, which Absorbs a One-Time Impact of Approximately $0.20 Related to 3SBio Transaction On Track to Deliver Approximately $7.2 Billion in Overall Anticipated Net Cost Savings from Previously Announced Cost Improvement Initiatives(4) by End of 2027, Driving Productivity Gains and Operating Margin Expansion Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates(5). Results for the second quarter and first six months of 2025 and 2024(6) are summarized below. ($ in millions, except per share amounts) Second-Quarter Six Months 2025 2024 % Change 2025 2024 % Change Revenues $ 14,653 $ 13,283 10% $ 28,367 $ 28,162 1% Reported(3) Net Income 2,910 41 * 5,877 3,156 86% Reported(3) Diluted EPS 0.51 0.01 * 1.03 0.55 86% Adjusted(2) Income 4,434 3,400 30% 9,671 8,074 20% Adjusted(2) Diluted EPS 0.78 0.60 30% 1.69 1.42 20% * Indicates calculation not meaningful or results are greater than 100%. REVENUES ($ in millions) Second-Quarter Six Months 2025 2024 % Change 2025 2024 % Change Total Oper. Total Oper. Global Biopharmaceuticals Business (Biopharma) $ 14,305 $ 12,991 10% 10% $ 27,746 $ 27,595 1% 1% Pfizer CentreOne (PC1) 328 278 18% 18% 585 535 9% 10% Pfizer Ignite 20 15 38% 38% 37 32 16% 16% TOTAL REVENUES $ 14,653 $ 13,283 10% 10% $ 28,367 $ 28,162 1% 2% 2025 FINANCIAL GUIDANCE(1) Reaffirms full-year 2025 Revenue guidance and raises Adjusted(2) diluted EPS guidance(1) by $0.10 at the midpoint to a range of $2.90 to $3.10. The updated 2025 Adjusted(2) diluted EPS guidance takes into consideration our strong year-to-date performance, continued confidence in our business, a favorable impact from foreign exchange, progress with ongoing cost improvement initiatives, and improvement in our effective tax rate. Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the licensing agreement with 3SBio, Inc. that will be recorded in the third quarter of 2025 with an expected unfavorable impact of approximately $0.20. The company's guidance absorbs the impact of the currently imposed tariffs from China, Canada, and Mexico, as well as potential price changes this year based on the letter received on July 31, 2025 from President Trump. Revenues $61.0 to $64.0 billion Adjusted(2) SI&A Expenses $13.1 to $14.1 billion (previously $13.3 to $14.3 billion) Adjusted(2) R&D Expenses $10.4 to $11.4 billion (previously $10.7 to $11.7 billion) Effective Tax Rate on Adjusted(2) Income Approximately 13.0% (previously approximately 15.0%) Adjusted(2) Diluted EPS $2.90 to $3.10 (previously $2.80 to $3.00) CAPITAL ALLOCATION During the first six months of 2025, Pfizer deployed its capital in a variety of ways, which primarily included: Reinvesting capital into initiatives intended to enhance the future growth prospects of the company, including: $4.7 billion invested in internal research and development projects, and Approximately $150 million invested in business development transactions. Separately, the completed 3SBio transaction will be recorded in third-quarter 2025. Returning capital directly to shareholders through $4.9 billion of cash dividends, or $0.86 per share of common stock. No share repurchases have been completed to date in 2025. As of August 5, 2025, Pfizer's remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2025. The company expects to continue to de-lever in a prudent manner in order to maintain a balanced capital allocation strategy. This includes maintaining the flexibility to deploy capital towards potential value-creating business development transactions and the potential to return capital to shareholders through share repurchases. Diluted weighted-average shares outstanding of 5,706 million and 5,696 million were used to calculate Reported(3) and Adjusted(2) diluted EPS for second-quarter 2025 and 2024, respectively. QUARTERLY FINANCIAL HIGHLIGHTS (Second-Quarter 2025 vs. Second-Quarter 2024) Second-quarter 2025 revenues totaled $14.7 billion, an increase of $1.4 billion, or 10%, compared to the prior-year quarter, reflecting an operational increase of $1.3 billion, or 10%, as well as a favorable impact of foreign exchange of $22 million. The operational increase was primarily driven by an increase in revenues for the Vyndaqel family, Comirnaty, Paxlovid, Padcev, Eliquis and several other products across categories despite the unfavorable impact of higher manufacturer discounts resulting from the Inflation Reduction Act (IRA) Medicare Part D Redesign. Second-quarter 2025 operational revenue growth was driven primarily by: Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 21% operationally, driven largely by strong demand with continuing uptake in patient diagnosis primarily in the U.S. and certain international developed markets, partially offset by lower net price in the U.S. mostly due to the impact of higher manufacturer discounts resulting from the IRA Medicare Part D Redesign; Comirnaty globally, up 95% operationally, driven primarily by higher net revenues in the U.S. partially due to higher market share, as well as higher contractual deliveries in certain international markets; Paxlovid globally, up 71% operationally, driven primarily by higher net price in the U.S. following the transition from the U.S. government agreement as well as a favorable adjustment of rebate accruals related to prior periods, partially offset by lower COVID-19 infections across the U.S. and certain international markets as well as lower international government purchases; Padcev globally, up 38% operationally, driven primarily by increased market share in first-line locally advanced or metastatic urothelial cancer (la/mUC), as well as a one-time favorable impact associated with the transition to a wholesaler distribution model in the U.S.; Eliquis globally, up 6% operationally, driven primarily by higher demand globally; partially offset by lower net price in the U.S., including the impact of higher manufacturer discounts resulting from the IRA Medicare Part D Redesign, and price erosion in certain international markets; Abrysvo globally, up 155% (or up $86 million) operationally, driven primarily by higher U.S. revenues from both a favorable net sales adjustment and higher demand for the maternal indication that more than offset lower vaccination rates for the older adult indication following an updated Advisory Committee on Immunization Practices (ACIP) recommendation; as well as launch uptake for both the adult and maternal indications in certain international markets; and Lorbrena globally, up 48% operationally, driven primarily by increased patient share in the first-line ALK-positive metastatic non-small cell lung cancer (ALK+ mNSCLC) treatment setting in the U.S., China, and certain other international markets, partially offset by lower net price in the U.S. mainly due to the impact of higher manufacturer discounts resulting from the IRA Medicare Part D Redesign; partially offset primarily by lower revenues for: Ibrance globally, down 8% operationally, driven primarily by lower net price in the U.S. largely due to the impact of higher manufacturer discounts resulting from the IRA Medicare Part D Redesign, as well as generic entry and timing of shipments in certain international markets. GAAP Reported(3) Statement of Operations Highlights SELECTED REPORTED(3) COSTS AND EXPENSES ($ in millions) Second-Quarter Six Months 2025 2024 % Change 2025 2024 % Change Total Oper. Total Oper. Cost of Sales(3) $ 3,778 $ 3,300 15 % 13 % $ 6,624 $ 6,679 (1 %) 1 % Percent of Revenues 25.8 % 24.8 % N/A N/A 23.4 % 23.7 % N/A N/A SI&A Expenses(3) 3,415 3,717 (8 %) (8 %) 6,446 7,212 (11 %) (10 %) R&D Expenses(3) 2,482 2,696 (8 %) (8 %) 4,685 5,189 (10 %) (10 %) Acquired IPR&D Expenses(3) 2 6 (68 %) (68 %) 11 6 72 % 72 % Other (Income)/Deductions—net(3) 739 1,107 (33 %) (33 %) 1,692 1,787 (5 %) — Effective Tax Rate on Reported(3) Income 4.6 % 130.2 % (0.8 %) 4.8 % Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision to accrued royalties recorded in the second quarter of 2024, partially offset by lower amortization from the step-up of acquired inventory. Second-quarter 2025 SI&A Expenses(3) decreased 8% operationally compared with the prior-year quarter, primarily reflecting focused investments and ongoing productivity improvements that drove a decrease in marketing and promotional spend for various products and lower spending in corporate enabling functions. Second-quarter 2025 R&D Expenses(3) decreased 8% operationally compared with the prior-year quarter, driven primarily by a net decrease in spending due to pipeline focus and optimization, as well as lower compensation-related expenses. The favorable period-over-period change in Other (income)/deductions—net(3) of $367 million for the second quarter of 2025, compared with the prior-year quarter, was driven primarily by (i) net gains on equity securities in the second quarter of 2025 versus net losses on equity securities in the second quarter of 2024, (ii) lower net interest expense and (iii) lower intangible asset impairment charges; partially offset by (iv) higher charges for certain legal matters. Pfizer's effective tax rate on Reported(3) income for the second quarter of 2025 decreased compared to the prior-year quarter primarily due to a favorable change in the jurisdictional mix of earnings. Adjusted(2) Statement of Operations Highlights SELECTED ADJUSTED(2) COSTS AND EXPENSES ($ in millions) Second-Quarter Six Months 2025 2024 % Change 2025 2024 % Change Total Oper. Total Oper. Adjusted(2) Cost of Sales $ 3,503 $ 2,768 27 % 24 % $ 6,096 $ 5,804 5 % 8 % Percent of Revenues 23.9 % 20.8 % N/A N/A 21.5 % 20.6 % N/A N/A Adjusted(2) SI&A Expenses 3,395 3,669 (7 %) (8 %) 6,404 7,123 (10 %) (10 %) Adjusted(2) R&D Expenses 2,438 2,671 (9 %) (9 %) 4,611 5,147 (10 %) (10 %) Adjusted(2) Other (Income)/Deductions—net 186 258 (28 %) (27 %) 431 555 (22 %) (5 %) Effective Tax Rate on Adjusted(2) Income 13.2 % 12.9 % 10.3 % 15.1 % See the reconciliations of certain Reported(3) to non-GAAP Adjusted(2) financial measures and associated footnotes in the financial tables section of this press release located at the hyperlink below. RECENT NOTABLE DEVELOPMENTS (Since April 29, 2025) Product Developments Product/Project Milestone Recent Development Link Braftovi (encorafenib) Phase 3Results May 2025. Announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating Braftovi in combination with cetuximab and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The results showed the Braftovi combination regimen reduced the risk of death by 51% (a key secondary endpoint) and reduced the risk of disease progression or death by 47% (a co-primary endpoint) compared to standard-of-care chemotherapy with or without bevacizumab. At the time of analysis, the safety profile of Braftovi in combination with cetuximab and mFOLFOX6 continued to be consistent with the known safety profile of each respective agent. No new safety signals were identified. Based on these results, the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) to support potential conversion to full approval with a decision expected in the first quarter of 2026. Full Release Comirnaty (COVID-19 Vaccine, mRNA) Regulatory July 2025. Pfizer and BioNTech announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies' LP.8.1-adapted monovalent COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA's Emergency Task Force to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. Subsequently, the European Commission authorized the vaccine on July 25, 2025. Full Release Regulatory June 2025. Pfizer and BioNTech submitted a regulatory application to the FDA requesting approval of Comirnaty 2025-2026 Formula targeting the Omicron sub-variant LP.8.1. N/A Hympavzi (marstacimab) Phase 3Results June 2025. Announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating Hympavzi for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous Hympavzi in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment approaches are needed. Hympavzi was generally well-tolerated in the study. Full Release Talzenna (talazoparib) Regulatory June 2025. Announced the FDA's decision on the sNDA for Talzenna in combination with Xtandi for men with metastatic castration-resistant prostate cancer (mCRPC). The FDA approved updated labelling with the inclusion of final overall survival (OS) data for the combination's existing indication for the treatment of adults with homologous recombination repair (HRR) gene-mutated mCRPC but did not expand the indication to include patients with non-HRR gene mutated mCRPC. As a result of the FDA's decision, Pfizer will no longer pursue an expanded indication for this combination in mCRPC in the U.S. Full Release Xtandi (enzalutamide) Phase 3Results July 2025. Astellas Pharma Inc. and Pfizer announced positive topline results from the OS analysis from the Phase 3 EMBARK study evaluating Xtandi, in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis. For patients treated with Xtandi plus leuprolide, a statistically significant and clinically meaningful improvement in OS was observed versus placebo plus leuprolide. A favorable trend towards improved OS was shown for Xtandi as monotherapy, however the difference did not reach statistical significance. Safety results were consistent with the demonstrated safety profile of Xtandi, with no new safety signals observed in the analysis. Full Release Phase 3Results May 2025. Astellas Pharma Inc. and Pfizer announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES (NCT02677896) study, reporting a five-year follow up of OS benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with Xtandi plus androgen deprivation therapy (ADT) compared to placebo plus ADT. The incidence of treatment-emergent adverse events in the five-year follow-up is consistent with prior ARCHES analyses and no new safety signals were identified. Full Release Pipeline Developments A comprehensive update of Pfizer's development pipeline was published today and is now available at It includes an overview of Pfizer's research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration. Product/Project Milestone Recent Development Link vepdegestrant Phase 3Results May 2025. Arvinas, Inc. and Pfizer announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. The VERITAC-2 results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) among patients with an estrogen receptor 1 mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat population. Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events. Full Release Corporate Developments Topic Recent Development Link Eliquis 360 Support July 2025. The Bristol Myers Squibb-Pfizer Alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the Alliance's patient resource Eliquis 360 Support, offering an opportunity for eligible cash-paying patients with a prescription to pay a discounted rate of more than 40% less than the current list price beginning September 8, 2025. Full Release Business Development July 2025. Announced the completion of an exclusive global, ex-China, in-licensing agreement with 3SBio, Inc., a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the terms of the agreement, 3SBio and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd. granted Pfizer an exclusive global license to develop, manufacture and commercialize SSGJ-707 worldwide, with an option to develop and commercialize in China. 3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion as well as tiered double-digit royalties on sales of SSGJ-707, if approved. In exchange for an option to the exclusive rights in China, Pfizer will make an upfront payment to 3SBio of $100 million and, in the event the option is exercised, would pay an option exercise fee of up to $50 million depending on future events. Pfizer has also made a $100 million equity investment in 3SBio. Full Release PFIZER TO HOST CONFERENCE CALL Please find Pfizer's press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink: (Note: If clicking on the above link does not open a new webpage, you may need to cut and paste the above URL into your browser's address bar.) Pfizer will host a live conference call and webcast today at 10:00 AM EDT. To access the live conference call and view the second-quarter 2025 earnings presentation, accompanying prepared remarks from management, and infographic, visit our website at You can also listen to the conference call by dialing either 800-456-4352 in the U.S. and Canada or 785-424-1086 outside of the U.S. and Canada. The passcode is "49385". The transcript and webcast replay of the call will be made available on our website at within 24 hours after the end of the live conference call and will be accessible for at least 90 days. For additional details, see the financial schedules and product revenue tables within the press release located at the hyperlink above, and the attached disclosure notice. (1) Pfizer does not provide guidance for U.S. generally accepted accounting principles (GAAP) Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period. Financial guidance for full-year 2025 reflects the following: Does not assume the completion of any business development transactions not completed as of August 5, 2025. An anticipated unfavorable revenue impact of approximately $0.5 billion due to recent and expected generic and biosimilar competition for certain products that have recently lost patent or regulatory protection or that are anticipated to lose patent or regulatory protection. Exchange rates assumed are a blend of actual rates in effect through second-quarter 2025 and mid-July 2025 rates for the remainder of the year. Guidance for Adjusted(2) diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.72 billion shares, and assumes no share repurchases in 2025. The company's guidance absorbs the impact of the currently imposed tariffs from China, Canada, and Mexico, as well as potential price changes this year based on the letter received on July 31, 2025 from President Trump. (2) Adjusted income and Adjusted diluted earnings per share (EPS) are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and U.S. GAAP diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the accompanying reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the second quarter and the first six months of 2025 and 2024 in the press release at the hyperlink above. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS(3). See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2024 Annual Report on Form 10-K and the accompanying Non-GAAP Financial Measure: Adjusted Income section of the press release located at the hyperlink above for a definition of each component of Adjusted income as well as other relevant information. (3) Revenues is defined as revenues in accordance with U.S. GAAP. Reported net income and its components are defined as net income attributable to Pfizer Inc. common shareholders and its components in accordance with U.S. GAAP. Reported diluted EPS is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. (4) On track to deliver approximately $7.7 billion in anticipated overall savings (approximately $7.2 billion of net cost savings) from previously announced cost improvement initiatives: Approximately $4.5 billion of overall net cost savings from Pfizer's ongoing cost realignment program are expected to be achieved by the end of 2025. An additional approximately $1.2 billion of anticipated net cost savings, primarily in SI&A, is expected to be fully achieved by the end of 2027. The net cost savings are calculated versus the midpoint of Pfizer's 2023 SI&A and R&D expense guidance provided on August 1, 2023. On track to deliver anticipated R&D re-organization cost savings of approximately $500 million to be fully realized by the end of 2026, with savings to be reinvested in the pipeline. The first phase of the Manufacturing Optimization Program is on track to deliver approximately $1.5 billion in net cost savings by the end of 2027, with initial savings anticipated in the latter part of 2025. (5) References to operational variances in this press release pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of Pfizer's business, they are not within Pfizer's control and because they can mask positive or negative trends in the business, Pfizer believes presenting operational variances excluding these foreign exchange changes provides useful information to evaluate Pfizer's results. (6) Pfizer's fiscal year-end for international subsidiaries is November 30 while Pfizer's fiscal year-end for U.S. subsidiaries is December 31. Therefore, Pfizer's second quarter and first six months for U.S. subsidiaries reflects the three and six months ended on June 29, 2025 and June 30, 2024, while Pfizer's second quarter and first six months for subsidiaries operating outside the U.S. reflects the three and six months ended on May 25, 2025 and May 26, 2024. DISCLOSURE NOTICE: Except where otherwise noted, the information contained in this earnings release and the related attachments is as of August 5, 2025. We assume no obligation to update any forward-looking statements contained in this earnings release and the related attachments as a result of new information or future events or developments. This earnings release and the related attachments contain forward-looking statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; reorganizations; business plans, strategy, goals and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, discontinuations, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, including demand, market size and utilization rates and growth, performance, timing of exclusivity and potential benefits; potential impact of tariffs and pricing dynamics; strategic reviews; leverage and capital allocation objectives; an enterprise-wide cost realignment program (including anticipated costs, savings and potential benefits); a Manufacturing Optimization Program to reduce our cost of goods sold (including anticipated costs, savings and potential benefits); dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, including our acquisition of Seagen and our licensing agreement with 3SBio, and our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our ongoing efforts to respond to COVID-19; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and the expected seasonality of demand for certain of our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions and we cannot assure you that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as "will," "may," "could," "likely," "ongoing," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "assume," "target," "forecast," "guidance," "goal," "objective," "aim," "seek," "potential," "hope" and other words and terms of similar meaning. Pfizer's financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: Risks Related to Our Business, Industry and Operations, and Business Development: the outcome of research and development (R&D) activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations; and uncertainties regarding the future development of our product candidates, including whether or when our product candidates will advance to future studies or phases of development or whether or when regulatory applications may be filed for any of our product candidates; our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; regulatory decisions impacting labeling, approval or authorization, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; uncertainties regarding the ability to obtain or maintain, and the scope of, recommendations by technical or advisory committees, and the timing of, and ability to obtain, pricing approvals and product launches, all of which could impact the availability or commercial potential of our products and product candidates; claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the conduct or outcome of post-approval clinical trials, pharmacovigilance or Risk Evaluation and Mitigation Strategies, which could impact marketing approval, product labeling, and/or availability or commercial potential; the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which has in the past and could in the future result in increased leverage and/or a downgrade of our credit ratings and could limit our ability to obtain future financing; challenges integrating the businesses and operations; disruption to business or operations relationships; risks related to growing revenues for certain acquired or partnered products; significant transaction costs; and unknown liabilities; competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates; the ability to successfully market both new and existing products, including biosimilars; difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions; the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&D and clinical trials; risks and uncertainties related to Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, including, among others, the risk that as the market for COVID-19 products remains endemic and seasonal and/or COVID-19 infection rates do not follow prior patterns, demand for our COVID-19 products has and may continue to be reduced or not meet expectations, which has in the past and may continue to lead to reduced revenues, excess inventory or other unanticipated charges; risks related to our ability to develop and commercialize variant adapted vaccines, combinations and/or treatments; uncertainties related to recommendations and coverage for, and the public's adherence to, vaccines, boosters, treatments or combinations, including uncertainties related to the potential impact of narrowing recommended patient populations; whether or when our EUAs or biologics licenses will expire, terminate or be revoked; and potential third-party royalties or other claims related to Comirnaty and Paxlovid; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; interest rate and foreign currency exchange rate fluctuations, including the impact of global trade tensions, as well as currency devaluations and monetary policy actions in countries experiencing high inflation or deflation rates; any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues; the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain; any significant issues related to the outsourcing of certain operational and staff functions to third parties; any significant issues related to our JVs and other third-party business arrangements, including modifications or disputes related to supply agreements or other contracts with customers including governments or other payors; uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation or interest rate fluctuations, and recent and possible future changes in global financial markets; the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions, tariffs and/or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy regarding tariffs or other trade policy; the risk and impact of tariffs on our business, which is subject to a number of factors including, but not limited to, restrictions on trade, the effective date and duration of such tariffs, countries included in the scope of tariffs, changes to amounts of tariffs, and potential retaliatory tariffs or other retaliatory actions imposed by other countries; the impact of disruptions related to climate change and natural disasters; any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the resulting economic or other consequences; the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, such as our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines, and our voluntary withdrawal of all lots of Oxbryta in all markets where it is approved and any regulatory or other impact on Oxbryta and other sickle cell disease assets; trade buying patterns; the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments; the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, including any potential future phases, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences; the ability to successfully achieve our climate-related goals and progress our environmental sustainability and other priorities; Risks Related to Government Regulation and Legal Proceedings: the impact of any U.S. healthcare reform or legislation, including executive orders or other change in laws, regulations or policy, or any significant spending reduction or cost control efforts affecting Medicare, Medicaid, the 340B Drug Pricing Program or other publicly funded or subsidized health programs, including the Inflation Reduction Act of 2022 (IRA) and the IRA Medicare Part D Redesign, or changes in the tax treatment of employer-sponsored health insurance that may be implemented; U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, including the potential for international reference pricing, including Most- Favored-Nation drug pricing, intellectual property, reimbursement or access to or recommendations for our medicines and vaccines, taxes or other restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive biopharmaceutical markets; risks and uncertainties related to changes to vaccine or other healthcare policy in the U.S.; legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medical regulation, environmental protections, data protection and cybersecurity, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain products to control costs in those markets; legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to legal proceedings and actual or alleged environmental contamination; the risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings; the risk and impact of tax related litigation and investigations; governmental laws, regulations and policies affecting our operations, including, without limitation, the IRA, as well as changes in such laws, regulations or policies or their interpretation, including, among others, new or changes in tariffs, tax laws and regulations internationally and in the U.S., including the One Big Beautiful Bill Act, which was enacted on July 4, 2025, and is still subject to further guidance; the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024, government cost-cutting measures and related impacts on, among other matters, government staffing, resources and ability to timely review and process regulatory or other submissions; restrictions related to certain data transfers and transactions involving certain countries; and potential changes to existing tax laws, tariffs, or changes to other laws, regulations or policies in the U.S., including by the U.S. Presidential administration and Congress, as well as in other countries; Risks Related to Intellectual Property, Technology and Cybersecurity: the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; risks to our products, patents and other intellectual property, such as: (i) claims of invalidity that could result in loss of patent coverage; (ii) claims of patent infringement, including asserted and/or unasserted intellectual property claims; (iii) claims we may assert against intellectual property rights held by third parties; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights; or (v) any pressure from, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products; any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services); any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack, which may include those using adversarial artificial intelligence techniques, or other malfeasance by, but not limited to, nation states, employees, business partners or others; and risks and challenges related to the use of software and services that include artificial intelligence-based functionality and other emerging technologies. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q, in each case including in the sections thereof captioned "Forward-Looking Information and Factors That May Affect Future Results" and "Item 1A. Risk Factors," and in our subsequent reports on Form 8-K. This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether. The information contained on our website or any third-party website is not incorporated by reference into this earnings release. All trademarks mentioned are the property of their owners. Certain of the products and product candidates discussed in this earnings release are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer's rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets. View source version on Contacts Media PfizerMediaRelations@ 212.733.1226Investors IR@ 212.733.4848
Yahoo
11 minutes ago
- Yahoo
Cat Financial Announces Second-Quarter 2025 Results
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cat Financial reported second-quarter 2025 revenues of $899 million, an increase of $34 million, or 4%, compared with $865 million in the second quarter of 2024. The increase in revenues was primarily due to a favorable impact from higher average earning assets of $49 million, partially offset by an unfavorable impact from lower average financing rates of $20 million. Second-quarter 2025 profit was $137 million compared with a $65 million loss in the second quarter of 2024. Second-quarter 2025 profit before income taxes was $183 million, an increase of $201 million compared with an $18 million loss in the second quarter of 2024. The increase was mainly driven by the absence of a $210 million loss on divestiture of a non-U.S. entity in 2024 and a favorable impact from higher average earning assets of $20 million, partially offset by higher provision for credit losses of $13 million and an unfavorable impact from lower margin of $10 million. The provision for income taxes for the second quarter of 2025 was $45 million on $183 million profit before income taxes compared with $47 million on $18 million loss before income taxes for the second quarter of 2024. The effective tax rate for the second quarter of 2024 was negatively impacted by the loss on divestiture of a non-U.S. entity with no related tax benefit. During the second quarter of 2025, retail new business volume was $3.60 billion, an increase of $187 million, or 5%, compared with $3.41 billion in the second quarter of 2024. The increase was primarily driven by higher volume in the Power, EAME and North America segments. At the end of the second quarter of 2025, past dues at Cat Financial were 1.62%, compared with 1.74% at the end of the second quarter of 2024. Write-offs, net of recoveries, were $18 million for both the second quarter of 2025 and the second quarter of 2024. As of June 30, 2025, Cat Financial's allowance for credit losses totaled $290 million, or 0.94% of finance receivables, compared with $282 million or 0.95% of finance receivables at March 31, 2025. The allowance for credit losses at year-end 2024 was $267 million, or 0.91% of finance receivables. "We continue to see solid new business volume and strong portfolio performance," said Dave Walton, President of Cat Financial and Senior Vice President with responsibility for the Financial Products Division of Caterpillar Inc. "The Cat Financial team remains focused on execution of our strategy and supporting Caterpillar customers and dealers with financial services solutions." About Cat Financial Cat Financial is a subsidiary of Caterpillar, the world's leading manufacturer of construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. Cat Financial provides a wide range of financing solutions to customers and Cat® dealers for machines, engines, Solar® turbines, genuine Cat parts and services. Headquartered in Nashville, Tennessee, Cat Financial serves customers globally with offices and subsidiaries located throughout North and South America, Asia, Australia, Europe and Africa. Visit to learn more about Cat Financial. STATISTICAL HIGHLIGHTS: SECOND-QUARTER 2025 VS. SECOND-QUARTER 2024 (ENDED JUNE 30, EXCEPT TOTAL ASSETS) (Millions of dollars) 20252024CHANGE Revenues $ 899$ 8654 % Profit (Loss) Before Income Taxes $ 183$ (18)1,117 % Profit (Loss) (excluding profit attributable to noncontrolling interests) $ 137$ (65)311 % Retail New Business Volume $ 3,599$ 3,4125 % Total Assets at June 30, and December 31, respectively $ 36,083$ 34,0846 %SIX MONTHS 2025 VS. SIX MONTHS 2024 (ENDED JUNE 30) (Millions of dollars) 20252024CHANGE Revenues $ 1,759$ 1,7182 % Profit (Loss) Before Income Taxes $ 357$ 21169 % Profit (Loss) (excluding profit attributable to noncontrolling interests) $ 267$ 104157 % Retail New Business Volume $ 6,563$ 6,1547 % FORWARD-LOOKING STATEMENTS Certain statements in this press release relate to future events and expectations and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "estimate," "will be," "will," "would," "expect," "anticipate," "plan," "project," "intend," "could," "should" or other similar words or expressions often identify forward-looking statements. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding our outlook, projections, forecasts or trend descriptions. These statements do not guarantee future performance and speak only as of the date they are made, and we do not undertake to update our forward-looking statements. Cat Financial's actual results may differ materially from those described or implied in our forward-looking statements based on a number of factors, including, but not limited to: (i) disruptions or volatility in global financial markets limiting our sources of liquidity or the liquidity of our customers, dealers and suppliers; (ii) failure to maintain our credit ratings and potential resulting increases to our cost of borrowing and adverse effects on our cost of funds, liquidity, competitive position and access to capital markets; (iii) changes in interest rates, currency fluctuations or market liquidity conditions; (iv) an increase in delinquencies, repossessions or net losses of our customers; (v) residual values of leased equipment; (vi) our compliance with financial and other restrictive covenants in debt agreements; (vii) government monetary or fiscal policies; (viii) political and economic risks, commercial instability and events beyond our control in the countries in which we operate; (ix) demand for Caterpillar products; (x) marketing, operational or administrative support received from Caterpillar; (xi) our ability to develop, produce and market quality products that meet our customers' needs; (xii) information technology security threats and computer crime; (xiii) alleged or actual violations of trade or anti-corruption laws and regulations; (xiv) new regulations or changes in financial services regulations; (xv) additional tax expense or exposure; (xvi) changes in accounting guidance; (xvii) catastrophic events, including global pandemics such as the COVID-19 pandemic; and (xviii) other factors described in more detail in Cat Financial's Forms 10-Q, 10-K and other filings with the Securities and Exchange Commission. View original content to download multimedia: SOURCE Cat Financial Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
